Journal
JOURNAL OF NEUROLOGY
Volume 264, Issue 12, Pages 2491-2494Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00415-017-8622-9
Keywords
Multiple Sclerosis; Daclizumab; Natalizumab; Rebound; Disease reactivation; Relapse
Categories
Funding
- German Research Council (DFG) [CRC-TR-128]
Ask authors/readers for more resources
Discontinuation of natalizumab can lead to severe rebound of disease activity in patients with relapsing-remitting multiple sclerosis (RRMS); nevertheless, the treatment regimen in this clinical situation remains controversial. We report the case of a 25-year-old male patient with RRMS who was clinically stable under 3 years of natalizumab before treatment was stopped due to progressive multifocal leucencephalopathy (PML) safety concerns. After initiation of daclizumab, the patient suffered from disease reactivation, which was ultimately controlled by intravenous methylprednisolone and alemtuzumab treatment. Therefore, in some patients, daclizumab might not be sufficient to control disease activity after discontinuing natalizumab treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available